Chemicals
Build Your Comparison
Side-by-side financial analysisStock Comparison
ORGN vs GEVO vs LOOP vs CLNE vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals - Specialty
Oil & Gas Refining & Marketing
Banks - Diversified
ORGN vs GEVO vs LOOP vs CLNE vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals | Chemicals - Specialty | Chemicals - Specialty | Oil & Gas Refining & Marketing | Banks - Diversified |
| Market Cap | $6M | $375M | $40M | $410M | $908.57B |
| Revenue (TTM) | $14M | $174M | $514K | $439M | $280.33B |
| Net Income (TTM) | $-241M | $-34M | $-12M | $-99M | $57.05B |
| Gross Margin | -4.4% | 47.3% | -11.9% | 16.6% | 60.0% |
| Operating Margin | -459.3% | -4.6% | -19.7% | -8.2% | 25.9% |
| Forward P/E | — | — | — | — | 14.6x |
| Total Debt | $28M | $168M | $3M | $99M | $942.38B |
| Cash & Equiv. | $33M | $1M | $2M | $158M | $343.34B |
ORGN vs GEVO vs LOOP vs CLNE vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | Jun 26 | Return |
|---|---|---|---|
| Origin Materials, I… (ORGN) | 100 | 0.4 | -99.6% |
| Gevo, Inc. (GEVO) | 100 | 154.0 | +54.0% |
| Loop Industries, In… (LOOP) | 100 | 6.1 | -93.9% |
| Clean Energy Fuels … (CLNE) | 100 | 75.0 | -25.0% |
| JPMorgan Chase & Co. (JPM) | 100 | 337.8 | +237.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORGN vs GEVO vs LOOP vs CLNE vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ORGN lags the leaders in this set but could rank higher in a more targeted comparison.
GEVO ranks third and is worth considering specifically for growth exposure.
- Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
- 8.5% revenue growth vs LOOP's -95.3%
Among these 5 stocks, LOOP doesn't own a clear edge in any measured category.
CLNE is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.48, Low D/E 17.5%, current ratio 2.32x
- Beta 0.48, current ratio 2.32x
- Better valuation composite
- Beta 0.48 vs ORGN's 1.54, lower leverage
JPM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.87, yield 1.8%
- 481.2% 10Y total return vs CLNE's -45.1%
- 20.4% margin vs LOOP's -23.9%
- 1.8% yield; 15-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.5% revenue growth vs LOOP's -95.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 20.4% margin vs LOOP's -23.9% | |
| Stability / Safety | Beta 0.48 vs ORGN's 1.54, lower leverage | |
| Dividends | 1.8% yield; 15-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +20.9% vs ORGN's -91.8% | |
| Efficiency (ROA) | 1.3% ROA vs LOOP's -100.3% |
ORGN vs GEVO vs LOOP vs CLNE vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ORGN vs GEVO vs LOOP vs CLNE vs JPM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 4 of 6 categories
ORGN leads 1 • GEVO leads 0 • LOOP leads 0 • CLNE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 545394.9x LOOP's $514,000. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to LOOP's -23.9%. On growth, GEVO holds the edge at +47.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $14M | $174M | $514,000 | $439M | $280.3B |
| EBITDAEarnings before interest/tax | -$55M | $21M | -$10M | $11M | $81.4B |
| Net IncomeAfter-tax profit | -$241M | -$34M | -$12M | -$99M | $57.0B |
| Free Cash FlowCash after capex | -$59M | -$44M | -$10M | $19M | $100.9B |
| Gross MarginGross profit ÷ Revenue | -4.4% | +47.3% | -11.9% | +16.6% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -4.6% | -4.6% | -19.7% | -8.2% | +25.9% |
| Net MarginNet income ÷ Revenue | -17.2% | -19.4% | -23.9% | -22.7% | +20.4% |
| FCF MarginFCF ÷ Revenue | -4.3% | -25.0% | -19.9% | +4.3% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -91.2% | +47.5% | -98.4% | +12.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +39.3% | +2.1% | -138.7% | +90.6% | +16.0% |
Valuation Metrics
ORGN leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, JPM's 18.5x EV/EBITDA is more attractive than GEVO's 83.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $6M | $375M | $40M | $410M | $908.6B |
| Enterprise ValueMkt cap + debt − cash | $781,018 | $541M | $41M | $351M | $1.51T |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | -11.00x | -3.19x | -1.84x | 16.22x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 14.60x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.92x |
| EV / EBITDAEnterprise value multiple | — | 83.82x | — | 74.09x | 18.52x |
| Price / SalesMarket cap ÷ Revenue | 0.32x | 2.33x | 78.12x | 0.96x | 3.25x |
| Price / BookPrice ÷ Book value/share | 0.05x | 0.76x | — | 0.73x | 2.51x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 6.84x | 9.01x |
Profitability & Efficiency
JPM leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-121 for ORGN. CLNE carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), CLNE scores 5/9 vs LOOP's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -120.7% | -7.2% | — | -17.2% | +15.9% |
| ROA (TTM)Return on assets | -99.5% | -4.9% | -100.3% | -9.2% | +1.3% |
| ROICReturn on invested capital | -24.4% | -2.8% | — | -9.4% | +4.5% |
| ROCEReturn on capital employed | -25.7% | -3.1% | -99.2% | -9.4% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 1 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.27x | 0.36x | — | 0.18x | 2.60x |
| Net DebtTotal debt minus cash | -$5M | $166M | $679,000 | -$59M | $599.0B |
| Cash & Equiv.Liquid assets | $33M | $1M | $2M | $158M | $343.3B |
| Total DebtShort + long-term debt | $28M | $168M | $3M | $99M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | -2627.81x | -0.66x | -6.22x | -0.71x | 0.74x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $37 for ORGN. Over the past 12 months, JPM leads with a +20.9% total return vs ORGN's -91.8%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs ORGN's -79.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -84.6% | -25.2% | -18.2% | -13.9% | +0.8% |
| 1-Year ReturnPast 12 months | -91.8% | +11.6% | -50.3% | -5.6% | +20.9% |
| 3-Year ReturnCumulative with dividends | -99.1% | +12.4% | -74.2% | -57.0% | +138.8% |
| 5-Year ReturnCumulative with dividends | -99.6% | -80.2% | -93.6% | -84.2% | +135.5% |
| 10-Year ReturnCumulative with dividends | -99.6% | -99.3% | -94.6% | -45.1% | +481.2% |
| CAGR (3Y)Annualised 3-year return | -79.4% | +4.0% | -36.3% | -24.5% | +33.7% |
Risk & Volatility
Evenly matched — CLNE and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
CLNE is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than ORGN's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 96.2% from its 52-week high vs ORGN's 3.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.54x | 1.52x | 0.74x | 0.48x | 0.87x |
| 52-Week HighHighest price in past year | $28.49 | $2.97 | $2.11 | $3.11 | $338.09 |
| 52-Week LowLowest price in past year | $0.20 | $1.12 | $0.73 | $1.75 | $269.72 |
| % of 52W HighCurrent price vs 52-week peak | +3.8% | +51.9% | +39.3% | +59.8% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 33.6 | 36.4 | 31.5 | 36.0 | 72.1 |
| Avg Volume (50D)Average daily shares traded | 563K | 3.4M | 57K | 1.2M | 7.4M |
Analyst Outlook
JPM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ORGN as "Buy", GEVO as "Buy", CLNE as "Buy", JPM as "Buy". Consensus price targets imply 8156.9% upside for ORGN (target: $90) vs 4.5% for JPM (target: $340). JPM is the only dividend payer here at 1.83% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $90.00 | $2.75 | — | $3.50 | $339.75 |
| # AnalystsCovering analysts | 6 | 14 | — | 22 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.8% |
| Dividend StreakConsecutive years of raises | 1 | — | 0 | — | 15 |
| Dividend / ShareAnnual DPS | — | — | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.9% | +3.8% |
JPM leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ORGN leads in 1 (Valuation Metrics). 1 tied.
ORGN vs GEVO vs LOOP vs CLNE vs JPM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ORGN or GEVO or LOOP or CLNE or JPM a better buy right now?
For growth investors, Gevo, Inc.
(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -95. 3% for Loop Industries, Inc. (LOOP). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ORGN or GEVO or LOOP or CLNE or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +135. 5%, compared to -99. 6% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: JPM returned +481. 2% versus ORGN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ORGN or GEVO or LOOP or CLNE or JPM?
By beta (market sensitivity over 5 years), Clean Energy Fuels Corp.
(CLNE) is the lower-risk stock at 0. 48β versus Origin Materials, Inc. 's 1. 54β — meaning ORGN is approximately 221% more volatile than CLNE relative to the S&P 500. On balance sheet safety, Clean Energy Fuels Corp. (CLNE) carries a lower debt/equity ratio of 18% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
04Which is growing faster — ORGN or GEVO or LOOP or CLNE or JPM?
By revenue growth (latest reported year), Gevo, Inc.
(GEVO) is pulling ahead at 849. 3% versus -95. 3% for Loop Industries, Inc. (LOOP). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -188. 2% for Origin Materials, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ORGN or GEVO or LOOP or CLNE or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -23. 9% for Loop Industries, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -1970. 4% for LOOP. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ORGN or GEVO or LOOP or CLNE or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for ORGN: 8156.
9% to $90. 00.
07Which pays a better dividend — ORGN or GEVO or LOOP or CLNE or JPM?
In this comparison, JPM (1.
8% yield) pays a dividend. ORGN, GEVO, LOOP, CLNE do not pay a meaningful dividend and should not be held primarily for income.
08Is ORGN or GEVO or LOOP or CLNE or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, ORGN: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ORGN and GEVO and LOOP and CLNE and JPM?
These companies operate in different sectors (ORGN (Basic Materials) and GEVO (Basic Materials) and LOOP (Basic Materials) and CLNE (Energy) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ORGN is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock; LOOP is a small-cap quality compounder stock; CLNE is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ORGN, GEVO, LOOP, CLNE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.